{"id":14849,"date":"2025-03-18T19:03:12","date_gmt":"2025-03-18T17:03:12","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=14849"},"modified":"2025-03-18T19:03:12","modified_gmt":"2025-03-18T17:03:12","slug":"18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/","title":{"rendered":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h3 style=\"text-align: center;\"><span style=\"color: #283583;\"><span class=\"TextRun SCXW54512012 BCX0\" lang=\"FR-FR\" xml:lang=\"FR-FR\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW54512012 BCX0\">MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te<\/span><\/span><\/span><\/h3>\n[\/vc_column_text][vc_column_text]\n<ul>\n<li>Le Comit\u00e9 ind\u00e9pendant de surveillance et de s\u00e9curit\u00e9 (Data Safety Monitoring Board &#8211; DSMB) a confirm\u00e9 les excellents r\u00e9sultats d\u2019efficacit\u00e9 ainsi que le rapport b\u00e9n\u00e9fice\/risque de MaaT013 \u00e9tait favorable dans cette population de patients.<\/li>\n<li>La Soci\u00e9t\u00e9 pr\u00e9voit de d\u00e9poser une demande d&rsquo;autorisation aupr\u00e8s de l&rsquo;Agence Europ\u00e9enne des m\u00e9dicaments (EMA) en juin 2025, dans la perspective d\u2019une potentielle approbation mi-2026.<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong><span style=\"color: #283583;\">Lyon, France, 18 mars 2025 \u2013 18h00 CET \u2013 <a href=\"https:\/\/maat.swebwp.oci.eu\/\">MaaT Pharma<\/a> (EURONEXT\u00a0: MAAT &#8211; la \u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem Therapies<sup>TM<\/sup> (MET) visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers gr\u00e2ce \u00e0 la modulation du syst\u00e8me immunitaire, <\/span><\/strong>annonce, apr\u00e8s avoir re\u00e7u r\u00e9cemment l\u2019approbation de son Plan d&rsquo;Investigation P\u00e9diatrique (PIP) par le Comit\u00e9 P\u00e9diatrique de l&rsquo;EMA, que le DSMB a r\u00e9alis\u00e9 sa derni\u00e8re revue de s\u00e9curit\u00e9 pour l&rsquo;essai clinique pivotal de Phase 3 ARES, une \u00e9tude europ\u00e9enne, ouverte, \u00e0 un seul bras et multicentrique, \u00e9valuant l&rsquo;efficacit\u00e9 et la s\u00e9curit\u00e9 de MaaT013 chez des patients atteints de la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te avec atteinte gastro-intestinale (GI-aGvH), en troisi\u00e8me ligne de traitement, r\u00e9fractaires aux st\u00e9ro\u00efdes et r\u00e9fractaires ou intol\u00e9rants au ruxolitinib.<\/p>\n<p><em>\u00ab La conclusion positive du DSMB marque une \u00e9tape cl\u00e9 pour MaaT Pharma, confirmant une nouvelle fois le profil clinique favorable de MaaT013 d\u00e9montr\u00e9 au fil des ann\u00e9es dans le d\u00e9veloppement clinique aupr\u00e8s d\u2019une population de patients particuli\u00e8rement vuln\u00e9rable \u00bb, <\/em><strong>a d\u00e9clar\u00e9 le docteur Gianfranco Pittari, PhD, Directeur M\u00e9dical de MaaT Pharma.<\/strong><em> \u00ab Cela r\u00e9affirme notre engagement \u00e0 am\u00e9liorer la survie des patients atteints d\u2018aGvH avec des traitements innovants. \u00bb<\/em><\/p>\n<p>L&rsquo;\u00e9tude de Phase 3 a atteint son objectif principal d\u2019\u00e9valuation et des r\u00e9sultats principaux positifs (<a href=\"https:\/\/maat.swebwp.oci.eu\/fr\/8-janvier-2025-maat-pharma-annonce-des-resultats-positifs-pour-letude-pivotale-de-phase-3-ares-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\">tous les d\u00e9tails ici<\/a>) ont \u00e9t\u00e9 communiqu\u00e9s en janvier 2025, d\u00e9montrant une efficacit\u00e9 \u00e9lev\u00e9e de MaaT013 avec un taux de r\u00e9ponse global gastro-intestinal significatif de 62% au 28\u00e8me jour, largement sup\u00e9rieur au taux de r\u00e9ponse attendu de 38%. Le DSMB, compos\u00e9 de 4 experts ind\u00e9pendants, avait pr\u00e9c\u00e9demment revu les donn\u00e9es portant sur 30 patients en octobre 2023 concluant que MaaT013 pr\u00e9sentait un <a href=\"https:\/\/maat.swebwp.oci.eu\/fr\/26-octobre-2023-maat-pharma-annonce-les-conclusions-positives-du-dsmb-renforcant-la-confiance-dans-lessai-de-phase-3-en-cours-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-l\/\">rapport b\u00e9n\u00e9fice\/risque favorable<\/a> sur la base d&rsquo;un bon profil de s\u00e9curit\u00e9 et de r\u00e9sultats pr\u00e9liminaires d&rsquo;efficacit\u00e9 positifs. Les experts ont examin\u00e9, lors de la derni\u00e8re r\u00e9union, les donn\u00e9es de s\u00e9curit\u00e9 portant sur 66 patients, jusqu&rsquo;\u00e0 la date limite de prise en compte des donn\u00e9es de l&rsquo;analyse primaire. Le DSMB a confirm\u00e9 \u00ab <em>qu&rsquo;au regard des excellents r\u00e9sultats d\u2019efficacit\u00e9, les r\u00e9sultats de l\u2019\u00e9tude d\u00e9montrent un profil de s\u00e9curit\u00e9 acceptable et un rapport b\u00e9n\u00e9fice\/risque favorable<\/em> \u00bb. Les membres du DSMB continueront \u00e0 suivre l\u2019\u00e9volution des donn\u00e9es de s\u00e9curit\u00e9 de mani\u00e8re continue jusqu\u2019au suivi \u00e0 un an.<\/p>\n<p><em>\u00ab Avec l\u2019approbation du Plan d\u2019Investigation P\u00e9diatrique par le Comit\u00e9 P\u00e9diatrique de l\u2019EMA et la conclusion positive du DSMB, nous poursuivons notre dynamique vers une potentielle obtention d\u2019une autorisation de mise sur le march\u00e9, avec l\u2019opportunit\u00e9 d\u2019avoir le premier m\u00e9dicament \u00e0 base de microbiote approuv\u00e9 en Europe \u00bb, <\/em><strong>conclut Herv\u00e9 Affagard, co-fondateur et directeur g\u00e9n\u00e9ral de MaaT Pharma.<\/strong><\/p>\n<p><strong>Prochaines \u00e9tapes pour MaaT013 en aGvH :<\/strong><\/p>\n<ul>\n<li>La soumission d\u2019une demande d\u2019Autorisation de Mise sur le March\u00e9 (AMM) aupr\u00e8s de l\u2019EMA via une proc\u00e9dure centralis\u00e9e est pr\u00e9vue en juin 2025.<\/li>\n<li>L\u2019\u00e9valuation de la survie globale \u00e0 un an (analyse du crit\u00e8re secondaire) est attendue au T4 2025.<\/li>\n<li>La Soci\u00e9t\u00e9 est \u00e9galement active aupr\u00e8s des investisseurs et partenaires potentiels afin de progresser vers la phase r\u00e9glementaire et la commercialisation.<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<span style=\"color: #283583;\"><strong>\u00c0 propos de la maladie du greffon contre l&rsquo;h\u00f4te aigu\u00eb<\/strong><\/span><\/p>\n<p>L\u2019aGvH survient chez les patients dans les 100 jours apr\u00e8s une greffe de cellules souches ou de moelle osseuse. Les cellules greff\u00e9es \u00ab\u00a0attaquent\u00a0\u00bb le receveur, provoquant une inflammation de la peau, du foie et\/ou du tractus gastro-intestinal et entra\u00eenant une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es. L&rsquo;atteinte gastro-intestinale notamment est associ\u00e9e \u00e0 des complications graves telles que diarrh\u00e9es intenses, douleurs abdominales, h\u00e9morragies intestinales et mettant en jeu le pronostic vital du patient, avec un risque de mortalit\u00e9 accru, en raison des difficult\u00e9s li\u00e9es \u00e0 la prise en charge d&rsquo;une inflammation gastro-intestinale s\u00e9v\u00e8re et des risques associ\u00e9s d&rsquo;infection, de malnutrition et de d\u00e9faillance d&rsquo;organes. Le traitement th\u00e9rapeutique standard de premi\u00e8re ligne pour traiter l\u2019aGvH est le recours aux st\u00e9ro\u00efdes. Si les patients ne r\u00e9pondent pas aux st\u00e9ro\u00efdes, ils sont consid\u00e9r\u00e9s comme r\u00e9sistants (SR) et d&rsquo;autres traitements peuvent \u00eatre administr\u00e9s. Actuellement, le ruxolitinib est le traitement de deuxi\u00e8me intention de la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te r\u00e9fractaire aux st\u00e9ro\u00efdes. R\u00e9cemment, remestemcel\u2014L-rknd a \u00e9t\u00e9 approuv\u00e9 en d\u00e9cembre 2024 aux \u00c9tats-Unis sp\u00e9cifiquement pour une utilisation dans la population p\u00e9diatrique en tant que traitement de seconde ligne.[\/vc_column_text][vc_column_text]<span style=\"color: #283583;\"><strong>A propos de MaaT013<\/strong><\/span><\/p>\n<p>Les microbioth\u00e9rapies \u00e0 \u00e9cosyst\u00e8me complet (MET) d\u00e9velopp\u00e9es par MaaT Pharma sont con\u00e7ues pour tirer parti de l\u2019\u00e9cosyst\u00e8me complet du microbiote afin de r\u00e9tablir l&rsquo;\u00e9quilibre et de maximiser les avantages cliniques pour les patients souffrant de dysbiose s\u00e9v\u00e8re induite par le traitement dans les maladies aigu\u00ebs. MaaT013 est une <em>Microbiome Ecosystem Therapy<\/em> (microbioth\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet) pr\u00eate \u00e0 l\u2019emploi, standardis\u00e9e et issue d\u2019une combinaison de microbiotes de donneurs sains pour une utilisation dans les situations d\u2019urgence. Le produit est caract\u00e9ris\u00e9 par une diversit\u00e9 et une richesse \u00e9lev\u00e9es et standardis\u00e9es des esp\u00e8ces microbiennes qu\u2019il contient et la pr\u00e9sence de Butycore<sup>TM<\/sup> (ensemble de bact\u00e9ries produisant des m\u00e9tabolites anti-inflammatoires). MaaT013 a pour objectif de restaurer la relation symbiotique entre le microbiote intestinal du patient et son syst\u00e8me immunitaire, afin de corriger la r\u00e9activit\u00e9 et restaurer la tol\u00e9rance des fonctions immunitaires et ainsi de r\u00e9duire l\u2019aGvH gastro-intestinale r\u00e9sistante aux st\u00e9ro\u00efdes. MaaT013 a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin de la Food and Drug Administration (FDA) aux \u00c9tats-Unis et de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA).[\/vc_column_text][vc_column_text]<span style=\"color: #283583;\"><strong>A propos de MaaT Pharma<\/strong><\/span><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologie en phase clinique avanc\u00e9e, leader dans le d\u00e9veloppement de m\u00e9dicaments issus du microbiote intestinal d\u00e9di\u00e9s \u00e0 moduler le syst\u00e8me immunitaire des patients atteints de cancer et \u00e0 am\u00e9liorer leur survie. Soutenue par une \u00e9quipe experte qui s&rsquo;engage \u00e0 faire la diff\u00e9rence pour les patients du monde entier, la Soci\u00e9t\u00e9 a \u00e9t\u00e9 fond\u00e9e en 2014 et est bas\u00e9e \u00e0 Lyon en France.<\/p>\n<p>Pionni\u00e8re dans son domaine, MaaT Pharma d\u00e9veloppe le premier candidat-m\u00e9dicament immunomodulateur bas\u00e9 sur le microbiote intestinal en oncologie, actuellement en phase 3 d\u2019\u00e9valuation clinique. Gr\u00e2ce \u00e0 ses technologies propri\u00e9taires de \u00ab pooling \u00bb (combinaison de dons de microbiotes sains) et de co-culture microbienne, MaaT Pharma d\u00e9veloppe des m\u00e9dicaments standardis\u00e9s \u00e0 haute diversit\u00e9 bact\u00e9rienne, visant \u00e0 am\u00e9liorer la survie des patients atteints de cancer. MaaT Pharma est cot\u00e9e sur Euronext Paris (MAAT) depuis 2021.[\/vc_column_text][vc_column_text]<span style=\"color: #283583;\"><strong>Donn\u00e9es prospectives<\/strong><\/span><\/p>\n<p>Ce communiqu\u00e9 de presse contient des d\u00e9clarations prospectives. Toutes les d\u00e9clarations autres que les \u00e9nonc\u00e9s de faits historiques inclus dans le pr\u00e9sent communiqu\u00e9 de presse au sujet d&rsquo;\u00e9v\u00e9nements futurs sont sujettes \u00e0 (i) des changements sans pr\u00e9avis et (ii) des facteurs ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9. Ces d\u00e9clarations peuvent comprendre, sans s&rsquo;y limiter, tout \u00e9nonc\u00e9 pr\u00e9c\u00e9d\u00e9, suivi ou incluant des mots tels que \u00ab cibler \u00bb, \u00ab croire \u00bb, \u00ab s&rsquo;attendre \u00e0 \u00bb, \u00ab viser \u00bb, \u00ab avoir l&rsquo;intention de \u00bb, \u00ab pouvoir \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab estimer \u00bb, \u00ab planifier \u00bb, \u00ab projeter \u00bb, \u00ab vouloir \u00bb, \u00ab pouvoir avoir \u00bb, \u00ab susceptible de \u00bb, \u00ab probable \u00bb, \u00ab devoir \u00bb, \u00ab pr\u00e9visions \u00bb et d\u2019autres mots et termes ayant un sens similaire ou la forme n\u00e9gative qui en d\u00e9coule. Les d\u00e9clarations prospectives sont assujetties \u00e0 des risques et \u00e0 des incertitudes inh\u00e9rentes ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9 qui pourraient conduire \u00e0 ce que les r\u00e9sultats ou les performances r\u00e9els de la Soci\u00e9t\u00e9 diff\u00e8rent consid\u00e9rablement des r\u00e9sultats ou des performances attendus exprim\u00e9s ou sous-entendus dans ces d\u00e9clarations prospectives.[\/vc_column_text][image_with_animation image_url=\u00a0\u00bb6212&Prime; animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbT\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2025\/03\/250318_CP-MAAT-PHARMA-DSMB-ARES-VF.pdf\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[182,117,169,93,118,152,136,160,153],"category_press":[67],"year_press":[172],"class_list":{"0":"post-14849","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"tag-2025-fr","9":"tag-agvhd-fr","10":"tag-cancer-fr","11":"tag-gvh-fr","12":"tag-gvhd-fr","13":"tag-hematologie","14":"tag-microbiome-fr","15":"tag-microbiote","16":"tag-oncologie-fr","17":"category_press-clinical-fr","18":"year_press-2025-2"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&#039;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&#039;h\u00f4te - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&#039;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&#039;h\u00f4te - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T17:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te\",\"datePublished\":\"2025-03-18T17:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\"},\"wordCount\":2808,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"keywords\":[\"2025\",\"aGvHD\",\"Cancer\",\"GvH\",\"GvHD\",\"H\u00e9matologie\",\"microbiome\",\"Microbiote\",\"Oncologie\"],\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\",\"name\":\"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l'essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l'h\u00f4te - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"datePublished\":\"2025-03-18T17:03:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l'essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l'h\u00f4te - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l'essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l'h\u00f4te - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/","og_site_name":"MaaT Pharma","article_published_time":"2025-03-18T17:03:12+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te","datePublished":"2025-03-18T17:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/"},"wordCount":2808,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","keywords":["2025","aGvHD","Cancer","GvH","GvHD","H\u00e9matologie","microbiome","Microbiote","Oncologie"],"articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/","url":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/","name":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l'essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l'h\u00f4te - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2025-03-18T17:03:12+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"18 mars 2025 : MaaT Pharma annonce la conclusion positive de l\u2019examen final du DSMB pour l&rsquo;essai clinique pivotal de Phase 3 \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/14849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=14849"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/14849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=14849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=14849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=14849"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=14849"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=14849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}